Skip to content

EV / sales at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
+0.1×
Quest Diagnostics logo
Quest DiagnosticsDGX
2.4×0.0×
NeoGenomics logo
NeoGenomicsNEO
1.2×-0.2×
Veracyte logo
VeracyteVCYT
4.3×-0.4×
Guardant Health logo
Guardant HealthGH
11.8×+4.3×
Natera, Inc. logo
Natera, Inc.NTRA
11×+1.0×

Other financials

Income statement

See full
Revenue$200.4M+2.3%
Gross profit$137.6M+2.5%
Operating income-$30.7M-5.9%
Net income-$34.1M-34,000%
EPS (diluted)-$0.36

Balance sheet

See full
Cash & equivalents$126.0M+24.8%
Total debt$211.5M+34.2%
Total equity$337.4M-52.1%
Total assets$673.7M-33.0%

Cash flow

See full
Operating cash flow-$15.7M+3.7%
CapEx$18.8M+181%
Free cash flow-$19.7M+65.1%

Valuation

See full
Market cap$512.85M+13.1%
Enterprise value$598.35M+17.3%
P/S0.6×+0.1×

Profitability

See full
Gross margin70%0.0pp
Operating margin-46.9%-88.3pp
Net margin-48.2%-72.9pp
FCF margin-17%

Returns & leverage

See full
Return on equity-76.7%-98.4pp
Debt / equity0.6×+0.4×
Current ratio2.4×+0.5×

Where this comes from

Calculated from Myriad Genetics’s reported figures.

Based on the most recent quarter.

The official record: Myriad Genetics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Myriad Genetics's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Myriad Genetics's EV / sales?
Myriad Genetics (MYGN) reported EV / sales of 0.6× in Q1 2026.
How has Myriad Genetics's EV / sales changed year-over-year?
Myriad Genetics's EV / sales decreased by 41.4% year-over-year, from 1× to 0.6×.
What is the long-term trend for Myriad Genetics's EV / sales?
Over 5 years (2020 to 2025), Myriad Genetics's EV / sales has grown at a -22.5% compound annual growth rate (CAGR), from 2.7× to 0.8×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.